Sign In  |  Register  |  About Daly City  |  Contact Us

Daly City, CA
September 01, 2020 1:20pm
7-Day Forecast | Traffic

  • Search Hotels in Daly City

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Inventiva S.A. ADR (NQ: IVA )

2.680 +0.040 (+1.52%)
Streaming Delayed Price Updated: 3:56 PM EST, Nov 27, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Inventiva S.A. ADR

< Previous 1 2 3 4 Next >
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers 
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers Inventiva (NASDAQ:IVA) shares increased by 44.0% to $5.88 during Friday's regular session. The market value of their outstanding shares is at $247.6 million. 
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers Akanda (NASDAQ:AKAN) stock rose 27.1% to $0.52 during Friday's pre-market session. The company's market cap stands at $16.0 million. 
Via Benzinga
Why Avenue Therapeutics Is Trading Lower By 59%; Here Are 31 Stocks Moving Premarket
Gainers InVivo Therapeutics Holdings Corp. (NASDAQ: NVIV) shares rose 42.3% to $11.36 in pre-market trading after jumping 83% on Thursday. 
Via Benzinga
Inventiva's NASH Pact In China Represents 'Financially Prudent Pathway,' Says This Analyst
Via Benzinga
Inventiva Inks Licensing Pact With China-Based Sino Biopharm For NASH Candidate In Greater China
Via Benzinga
Why Aehr Test Systems Shares Are Trading Higher By Over 19%, Here Are 51 Stocks Moving In Friday's Mid-Day Session
Gainers Innovative Eyewear, Inc. (NASDAQ: LUCY) jumped 108% to $3.3943 on abnormally-high volume. The company released its October investor presentation yesterday. 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
We're starting the final day of trading this week with a breakdown of the biggest pre-market stock movers for Friday morning! 
Via InvestorPlace
Inventiva Raises €50M Debt Financing To Fund Its Lead Program In NASH Patients
Via Benzinga
Week In Review: Sino Biopharma Subsidiary Enters $307 Million Agreement For Rights To NASH Candidate
Chia Tai-Tianqing Pharma, a subsidiary of Sino Biopharma, in-licensed Greater China rights to a therapy for non-alcoholic steatohepatitis from Inventiva in a $307 million deal. Meanwhile, CASI Pharma... 
Via Talk Markets
Dow Turns Higher; Crude Oil Rises 0.7%
U.S. stocks pared some losses, with the Dow Jones turning higher toward the end of trading on Thursday. 
Via Benzinga
Why MediWound Is Trading Lower By Around 18%, Here Are 48 Stocks Moving In Thursday's Mid-Day Session
 Gainers 
Via Benzinga
Nasdaq Drops Over 100 Points; Spero Therapeutics Shares Spike Higher
U.S. stocks traded lower midway through trading, with the Nasdaq Composite dropping more than 100 points on Thursday. 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers Spero Therapeutics (NASDAQ:SPRO) shares moved upwards by 122.7% to $1.83 during Thursday's pre-market session. The market value of their outstanding shares is at $64.1 million. 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers Pulmatrix (NASDAQ:PULM) shares rose 11.9% to $4.3 during Wednesday's after-market session. The company's market cap stands at $14.5 million. 
Via Benzinga
Earnings Scheduled For September 21, 2022
Companies Reporting Before The Bell • General Mills (NYSE:GIS) is projected to report quarterly earnings at $1.00 per share on revenue of $4.72 billion. 
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
  Tuesday's session saw 63 companies set new 52-week lows. 
Via Benzinga
Stocks That Hit 52-Week Lows On Thursday
  During Thursday's trading, 50 companies set new 52-week lows. 
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
  Tuesday saw 37 companies set new 52-week lows. 
Via Benzinga
51 Biggest Movers From Yesterday
Gainers Advent Technologies Holdings, Inc. (NASDAQ: ADN) shares climbed 79.7% to close at $3.63 on Wednesday. Advent Technologies and Hyundai Motor Company entered into... 
Via Benzinga
40 Stocks Moving In Wednesday's Mid-Day Session
Gainers Advent Technologies Holdings, Inc. (NASDAQ: ADN) shares jumped 77.7% to $3.5950. Advent Technologies and Hyundai Motor Company entered into technology assessment, sales... 
Via Benzinga
21 Stocks Moving in Wednesday's Pre-Market Session
Gainers Dakota Gold (NYSE: DC) shares rose 97.1% to $13.60 in pre-market trading. The company’s stock was uplisted to NYSE American on Tuesday. BigBear.ai Holdings,... 
Via Benzinga
The Daily Biotech Pulse: Moderna Outlines Steps For mRNA Tech Advancement, Voyager-Novartis Strike Licensing Deal, Valneva Reports Positive Chikungunya Shot Readout
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Moderna Announces 4 Initiatives To Advance mRNA Vaccines As Preventative... 
Via Benzinga
FDA Gives Green Signal To Inventiva's Mid-Stage Lanifibranor Study In NASH Patients
The FDA has completed a safety review of Inventiva SA's (NASDAQ: IVA) IND application and signed off Phase 2 combination trial with its lead drug candidate... 
Via Benzinga
Earnings Scheduled For March 7, 2022
Companies Reporting Before The Bell • Niu Technologies (NASDAQ:NIU) is expected to report quarterly earnings at $0.21 per share on revenue of $144.02 million. •... 
Via Benzinga
The Daily Biotech Pulse: ImmunityBio Reports Positive Readout, Valneva Starts Late-Stage Chikungunya Vaccine Study, Sio Gene Shelves Parkinson's Program
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Inventiva Posts Results of Clinical Thorough QT Study Of Lanifibranor
Inventiva (NASDAQ: IVA) announced the results of a clinical thorough QT/QTc study demonstrating the safety of lanifibranor on cardiac electrical activity. The... 
Via Benzinga
Inventiva Plans To Start Lanifibranor Combo Study In NASH, Diabetes In 2022
Inventiva (NASDAQ: IVA) announced the design of Phase 2a combination trial of lanifibranor in patients with type 2 diabetes (T2D) and non-cirrhotic non-alcoholic... 
Via Benzinga
The Daily Biotech Pulse: Pfizer-BioNTech US Vaccine Contract, Summit Slumps On Adverse Regulatory Feedback, Cerevel CFO Departs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 20) Acceleron Pharma Inc. (... 
Via Benzinga
Fast Track Status Expanded For Inventiva's NASH Treatment
The FDA has decided that the Fast Track designation previously granted to Inventiva SA's (NASDAQ: IVA) lanifibranor in NASH encompasses the treatment of NASH... 
Via Benzinga
Exposures Product Safety
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 DalyCity.com & California Media Partners, LLC. All rights reserved.